McKesson to acquire Precision Medicine Group for $2.25bn

Deal structure and integration plan

McKesson has agreed to acquire Precision Medicine Group for $2.25bn, with Precision Medicine Group set to operate within McKesson once the transaction receives final regulatory and closing approvals. Upon completion, Precision Medicine Group will be housed under McKesson's oncology and multi-speciality segment. The deal remains subject to customary closing conditions, including regulatory approvals, and no closing date was disclosed in the reporting.

Strategic rationale and leadership comments

McKesson chair and CEO Brian Tyler framed the acquisition as an extension of the company's oncology and multi-speciality strategy. "This acquisition represents another meaningful step in advancing our oncology and multi-speciality strategy and reflects our continued commitment to providing patients with access to the highest quality of care," Tyler said. He added that Precision Medicine Group "brings complementary capabilities that will enhance our clinical research and commercialisation services, strengthen clinical trial execution, and broaden our clinical service offerings."

Precision Medicine Group CEO Margaret Keegan said: "Joining McKesson provides a compelling opportunity to extend the impact of our clinical and commercial expertise for the benefit of our customers, partners and patients they serve. Together, we will bring a broader set of capabilities to biopharma companies, supporting them through the development and commercialisation process."

Capabilities Precision Medicine Group brings

Precision Medicine Group was founded as a provider of global clinical research and commercialisation services for biotechnology and pharmaceutical companies. Its offerings include biomarker intelligence, laboratory services, a global clinical research organization, market access consulting, and commercialisation support. McKesson, which partners with biopharma companies, care providers and pharmacies, said the addition is intended to strengthen its clinical research and biopharmaceutical commercialisation services.

Transaction background and reporting chain

The acquisition was reported on August 26, 2026, with the Yahoo Finance/Hospital Management write-up carrying deal terms, executive quotations and closing-condition language. A separate BioXconomy headline, "McKesson Acquires Precision Medicine Group," corroborated the transaction on the same date. The Yahoo Finance article noted McKesson shares trading under the ticker MCK, showing a 0.93% move in the session, and was originally produced by Hospital Management, a GlobalData-owned brand.

Open questions and closing timeline

The transaction's expected closing date was not stated in the available reporting, and the specific regulatory clearances required were not identified. Pricing terms beyond the $2.25bn headline figure and any termination or break fee provisions were also not disclosed.